Skip to Main Content

Paper Details

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
J Immunother Cancer
29
2022
AGC, ATM, AZD6738, Ceralasertib, HRD, Rad3 related protein, Solid Tumors, advanced gastric cancer, ataxia telangiectasia, ataxia telangiectasia mutated, cancer, cell clones, ceralasertib, circulating tumor-reactive CD8 +T, cytosolic, cytosolic DNA, durvalumab, homologous repair deficiency, intratumoral lymphocytes, patients, tumor, tumor vasculature signature
Author NameAffiliation
Kyu-Tae KimAjou University
Kyu-Tae KimAjou University
Sung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Sung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Kyoung-Mee KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Woong-Yang ParkSamsung Genome Institute, Samsung Medical Center
Woong-Yang ParkSamsung Genome Institute, Samsung Medical Center
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine
Jeeyun LeeSungkyunkwan University
  • 1 - 9

Datasets

Release 1.2